Bioanalytical Syst (BASI) 1.17 $BASI
Bioanalytical (BASI) Launches Sampling System, Stock Down
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:10PM CDT
Bioanalytical recently introduced the 'Embrace Automation grant program' featuring 'BASi Culex NxT Automated Blood Sampling system and Raturn.'
HYH: 36.25 (-0.20), MASI: 59.43 (+0.29), BASI: 1.17 (+0.06), IDXX: 113.16 (+0.48)
BASi Launches Embrace Automation Grant Program with Culex NxT(TM) Automated Blood Sampling System
BusinessWire - Thu Aug 25, 7:30AM CDT
Bioanalytical Systems, Inc. (BASi) (NASDAQ:BASI), a recognized global leader in the development of instrumentation for automated blood sampling in animal models, is proud to announce its launch of the Embrace Automation grant program featuring the BASi Culex NxT (TM) Automated Blood Sampling system and Raturn(TM).
BASI: 1.17 (+0.06)
BASi Reports Third Quarter Results
BusinessWire - Thu Aug 11, 7:30AM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) ("BASi" or the "Company"
today announced financial results for the third quarter and first nine months of fiscal 2016.
BASI: 1.17 (+0.06)
Bioanalytical Systems to Release Third Quarter Fiscal 2016 Results on Thursday, August 11, 2016; Conference Call & Webcast Set For 11:00 am EDT
BusinessWire - Wed Aug 03, 9:05AM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) announced today that it will report financial results for the third quarter of fiscal 2016 ended June 30, 2016, prior to the market opening on Thursday, August 11, 2016. A conference call has been scheduled at 11:00 a.m. Eastern Daylight Time (EDT) to discuss the results. To participate in the call, dial (866) 865-2633, using Conference ID 56370380.
BASI: 1.17 (+0.06)
BASi Reports Second Quarter Results
BusinessWire - Thu May 12, 8:56AM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) ("BASi" or the "Company" today announced financial results for the second quarter and first six months of fiscal 2016.
BASI: 1.17 (+0.06)
Bioanalytical Systems, Inc. Announces Appointment of New Chief Financial Officer
BusinessWire - Wed May 11, 10:01AM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) ("BASi" or the "Company" on May 9, 2016, the Board of Directors of the Company approved the appointment of Jill C. Blumhoff, age 39, as Chief Financial Officer (CFO) and Vice President of Finance of the Company. Ms. Blumhoff succeeds Jeffrey Potrzebowski, age 63, effective with his retirement from the Company on May 9, 2016.
BASI: 1.17 (+0.06)
BASi Launches New Website and E-Catalogue
BusinessWire - Thu Apr 14, 1:10PM CDT
Bioanalytical Systems, Inc. ("BASi" (NASDAQ:BASI) today announced the launch of a new, redesigned version of its website, www.basinc.com. The site's refreshed and simplified look, combined with enhanced content, improved search functionality, and optimization for mobile devices allows customers and visitors to better interact with BASi online.
BASI: 1.17 (+0.06)
CORRECTING and REPLACING BASi Introduces the Next Generation of Electrochemical Analyzer With the Release of the Epsilon EClipse(TM)
BusinessWire - Tue Mar 29, 12:08PM CDT
Fourth paragraph, first sentence should read: The Epsilon EClipse(TM) with vastly improved user friendliness includes a modern Windows(R) interface, allows for opening an unlimited number of files and will be easier to view and select a variety of plots (instead of The Epsilon EClipse(TM) with vastly improved user friendliness includes a modern Windows(R) interface, it allows for opening an unlimited of files and it will be easier to view and select a variety of plots.)
BASI: 1.17 (+0.06)
BASi Introduces the Next Generation of Electrochemical Analyzer With the Release of the Epsilon EClipse(TM)
BusinessWire - Tue Mar 29, 8:11AM CDT
Bioanalytical Systems, Inc. (BASi) (NASDAQ:BASI), a leader in the development of instrumentation for bioanalytical separations and quantitative electroanalytical measurements is proud to introduce the Epsilon EClipse(TM) as the newest addition to its industry-leading Electrochemical Analyzer family of instrumentation.
BASI: 1.17 (+0.06)
Bioanalytical Systems to Release First Quarter Fiscal 2016 Results on Tuesday, February 16, 2016; Conference Call & Webcast Set For 11:00 a.m. EST
BusinessWire - Tue Feb 09, 9:00AM CST
Bioanalytical Systems, Inc. (NASDAQ:BASI) announced today that it will report financial results for the first quarter of fiscal 2016 ended December 31, 2015, prior to the market opening on Tuesday, February 16, 2016. A conference call has been scheduled at 11:00 a.m. Eastern Standard Time (EST) to discuss the results. To participate in the call, dial (866) 865-2633, using Conference ID 43800479.
BASI: 1.17 (+0.06)
BASi Awards Raturn(R) Systems for Optogenetic Research
BusinessWire - Thu Feb 04, 10:50AM CST
Bioanalytical Systems, Inc. (BASi) (NASDAQ:BASI) today announced it is awarding three BASi Raturn(R) Swivel-Free Sampling Systems to researchers who will integrate in vivo optogenetics techniques with data collection techniques. These related data collection techniques include microdialysis, biosensor detection, electrophysiological measurements, and behavioral readouts. Upon extensive review of the grant proposals, BASi determined the recipients based on their groundbreaking and forward-thinking approach to integrate BASi's Raturn(R) and expand the possibilities of collecting multiple data streams from a single animal. The recipients are: Robert Gross Laboratory at Emory University, David Holtzman Laboratory at Washington University School of Medicine and Michael Fanselow and Kate Wassum Laboratories at the University of California, Los Angeles.
BASI: 1.17 (+0.06)
BASi Reports Fiscal 2015 Full Year and Fourth Quarter Results
BusinessWire - Thu Dec 17, 8:04AM CST
Bioanalytical Systems, Inc. ("BASi" (NASDAQ:BASI) today announced financial results for the full fiscal year and fourth quarter ended September 30, 2015.
BASI: 1.17 (+0.06)
BASi Names Dawn M. Joseph Director of Business Development
BusinessWire - Tue Dec 15, 10:00AM CST
Bioanalytical Systems, Inc. ("BASi" (NASDAQ:BASI) today announced the appointment of Dawn M. Joseph as Director of Business Development reporting to BASi Vice President of Business Development, Connie Dougherty.
BASI: 1.17 (+0.06)
BASi Names Wendy Perrow to Board of Directors
BusinessWire - Mon Dec 14, 9:30AM CST
Bioanalytical Systems, Inc. ("BASi" (NASDAQ:BASI) today announced that its board of directors unanimously elected Ms. Wendy Perrow, President and Chief Executive Officer at Alba Therapeutics, as a director effective December 10, 2015. This action brings the number of directors to seven.
BASI: 1.17 (+0.06)
Bioanalytical Systems to Release Fourth Quarter and Full Year Fiscal 2015 Results on Thursday, December 17, 2015; Conference Call & Webcast Set For 11:00 a.m. EST
BusinessWire - Thu Dec 03, 2:45PM CST
Bioanalytical Systems, Inc. (NASDAQ:BASI) announced today that it will report financial results for the fourth quarter and full year for the ended September 30, 2015, prior to the market opening on Thursday, December 17, 2015. A conference call has been scheduled at 11:00 a.m. Eastern Standard Time (EST) to discuss the results. To participate in the call, dial (866) 865-2633.
BASI: 1.17 (+0.06)
BASi Reports Third Quarter Net Income of $0.16 per Share
BusinessWire - Thu Aug 13, 7:45AM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) ("BASi" or the "Company" today announced financial results for the third quarter and first nine months of fiscal 2015.
BASI: 1.17 (+0.06)
Bioanalytical Systems to Release Third Quarter Fiscal 2015 Results on Thursday, August 13, 2015; Conference Call & Webcast Set For 11:00 a.m. EDT
BusinessWire - Mon Aug 10, 1:56PM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) announced today that it will report financial results for the third quarter of fiscal 2015 ended June 30, 2015, prior to the market opening on Thursday, August 13, 2015. A conference call has been scheduled at 11:00 a.m. Eastern Daylight Time (EDT) to discuss the results. To participate in the call, dial (866) 865-2633, using passcode 2120136.
BASI: 1.17 (+0.06)
BUYINS.NET: BASI SqueezeTrigger Price is $1.92. There is $75,840 That Short Sellers Still Need To Cover.
M2 - Mon Jul 20, 7:28AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Bioanalytical Systems Inc (NASDAQ:BASI) in real time and just received an alert that BASI is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 39500 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $1.92. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
BASI: 1.17 (+0.06)
BASi Announces Enhancements to the Company's Laboratory Information Management System (LIMS)
BusinessWire - Tue Jul 14, 2:59PM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) has entered into an agreement with PDS Life Sciences (PDS) to fully upgrade its laboratory information management system (LIMS) to Ascentos(TM). The new Ascentos software represents the next generation of preclinical research LIMS and is a fully integrated software solution that includes toxicology, clinical pathology, toxicokinetics and pathology modules that streamline data management and reporting.
BASI: 1.17 (+0.06)
Bioanalytical (BASI) Launches Sampling System, Stock Down
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:10PM CDT
Bioanalytical recently introduced the 'Embrace Automation grant program' featuring 'BASi Culex NxT Automated Blood Sampling system and Raturn.'
HYH: 36.25 (-0.20), MASI: 59.43 (+0.29), BASI: 1.17 (+0.06), IDXX: 113.16 (+0.48)
BASi Launches Embrace Automation Grant Program with Culex NxT(TM) Automated Blood Sampling System
BusinessWire - Thu Aug 25, 7:30AM CDT
Bioanalytical Systems, Inc. (BASi) (NASDAQ:BASI), a recognized global leader in the development of instrumentation for automated blood sampling in animal models, is proud to announce its launch of the Embrace Automation grant program featuring the BASi Culex NxT (TM) Automated Blood Sampling system and Raturn(TM).
BASI: 1.17 (+0.06)
BASi Reports Third Quarter Results
BusinessWire - Thu Aug 11, 7:30AM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) ("BASi" or the "Company"
today announced financial results for the third quarter and first nine months of fiscal 2016. BASI: 1.17 (+0.06)
Bioanalytical Systems to Release Third Quarter Fiscal 2016 Results on Thursday, August 11, 2016; Conference Call & Webcast Set For 11:00 am EDT
BusinessWire - Wed Aug 03, 9:05AM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) announced today that it will report financial results for the third quarter of fiscal 2016 ended June 30, 2016, prior to the market opening on Thursday, August 11, 2016. A conference call has been scheduled at 11:00 a.m. Eastern Daylight Time (EDT) to discuss the results. To participate in the call, dial (866) 865-2633, using Conference ID 56370380.
BASI: 1.17 (+0.06)
BASi Reports Second Quarter Results
BusinessWire - Thu May 12, 8:56AM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) ("BASi" or the "Company"
today announced financial results for the second quarter and first six months of fiscal 2016. BASI: 1.17 (+0.06)
Bioanalytical Systems, Inc. Announces Appointment of New Chief Financial Officer
BusinessWire - Wed May 11, 10:01AM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) ("BASi" or the "Company"
on May 9, 2016, the Board of Directors of the Company approved the appointment of Jill C. Blumhoff, age 39, as Chief Financial Officer (CFO) and Vice President of Finance of the Company. Ms. Blumhoff succeeds Jeffrey Potrzebowski, age 63, effective with his retirement from the Company on May 9, 2016. BASI: 1.17 (+0.06)
BASi Launches New Website and E-Catalogue
BusinessWire - Thu Apr 14, 1:10PM CDT
Bioanalytical Systems, Inc. ("BASi"
(NASDAQ:BASI) today announced the launch of a new, redesigned version of its website, www.basinc.com. The site's refreshed and simplified look, combined with enhanced content, improved search functionality, and optimization for mobile devices allows customers and visitors to better interact with BASi online. BASI: 1.17 (+0.06)
CORRECTING and REPLACING BASi Introduces the Next Generation of Electrochemical Analyzer With the Release of the Epsilon EClipse(TM)
BusinessWire - Tue Mar 29, 12:08PM CDT
Fourth paragraph, first sentence should read: The Epsilon EClipse(TM) with vastly improved user friendliness includes a modern Windows(R) interface, allows for opening an unlimited number of files and will be easier to view and select a variety of plots (instead of The Epsilon EClipse(TM) with vastly improved user friendliness includes a modern Windows(R) interface, it allows for opening an unlimited of files and it will be easier to view and select a variety of plots.)
BASI: 1.17 (+0.06)
BASi Introduces the Next Generation of Electrochemical Analyzer With the Release of the Epsilon EClipse(TM)
BusinessWire - Tue Mar 29, 8:11AM CDT
Bioanalytical Systems, Inc. (BASi) (NASDAQ:BASI), a leader in the development of instrumentation for bioanalytical separations and quantitative electroanalytical measurements is proud to introduce the Epsilon EClipse(TM) as the newest addition to its industry-leading Electrochemical Analyzer family of instrumentation.
BASI: 1.17 (+0.06)
Bioanalytical Systems to Release First Quarter Fiscal 2016 Results on Tuesday, February 16, 2016; Conference Call & Webcast Set For 11:00 a.m. EST
BusinessWire - Tue Feb 09, 9:00AM CST
Bioanalytical Systems, Inc. (NASDAQ:BASI) announced today that it will report financial results for the first quarter of fiscal 2016 ended December 31, 2015, prior to the market opening on Tuesday, February 16, 2016. A conference call has been scheduled at 11:00 a.m. Eastern Standard Time (EST) to discuss the results. To participate in the call, dial (866) 865-2633, using Conference ID 43800479.
BASI: 1.17 (+0.06)
BASi Awards Raturn(R) Systems for Optogenetic Research
BusinessWire - Thu Feb 04, 10:50AM CST
Bioanalytical Systems, Inc. (BASi) (NASDAQ:BASI) today announced it is awarding three BASi Raturn(R) Swivel-Free Sampling Systems to researchers who will integrate in vivo optogenetics techniques with data collection techniques. These related data collection techniques include microdialysis, biosensor detection, electrophysiological measurements, and behavioral readouts. Upon extensive review of the grant proposals, BASi determined the recipients based on their groundbreaking and forward-thinking approach to integrate BASi's Raturn(R) and expand the possibilities of collecting multiple data streams from a single animal. The recipients are: Robert Gross Laboratory at Emory University, David Holtzman Laboratory at Washington University School of Medicine and Michael Fanselow and Kate Wassum Laboratories at the University of California, Los Angeles.
BASI: 1.17 (+0.06)
BASi Reports Fiscal 2015 Full Year and Fourth Quarter Results
BusinessWire - Thu Dec 17, 8:04AM CST
Bioanalytical Systems, Inc. ("BASi"
(NASDAQ:BASI) today announced financial results for the full fiscal year and fourth quarter ended September 30, 2015. BASI: 1.17 (+0.06)
BASi Names Dawn M. Joseph Director of Business Development
BusinessWire - Tue Dec 15, 10:00AM CST
Bioanalytical Systems, Inc. ("BASi"
(NASDAQ:BASI) today announced the appointment of Dawn M. Joseph as Director of Business Development reporting to BASi Vice President of Business Development, Connie Dougherty. BASI: 1.17 (+0.06)
BASi Names Wendy Perrow to Board of Directors
BusinessWire - Mon Dec 14, 9:30AM CST
Bioanalytical Systems, Inc. ("BASi"
(NASDAQ:BASI) today announced that its board of directors unanimously elected Ms. Wendy Perrow, President and Chief Executive Officer at Alba Therapeutics, as a director effective December 10, 2015. This action brings the number of directors to seven. BASI: 1.17 (+0.06)
Bioanalytical Systems to Release Fourth Quarter and Full Year Fiscal 2015 Results on Thursday, December 17, 2015; Conference Call & Webcast Set For 11:00 a.m. EST
BusinessWire - Thu Dec 03, 2:45PM CST
Bioanalytical Systems, Inc. (NASDAQ:BASI) announced today that it will report financial results for the fourth quarter and full year for the ended September 30, 2015, prior to the market opening on Thursday, December 17, 2015. A conference call has been scheduled at 11:00 a.m. Eastern Standard Time (EST) to discuss the results. To participate in the call, dial (866) 865-2633.
BASI: 1.17 (+0.06)
BASi Reports Third Quarter Net Income of $0.16 per Share
BusinessWire - Thu Aug 13, 7:45AM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) ("BASi" or the "Company"
today announced financial results for the third quarter and first nine months of fiscal 2015. BASI: 1.17 (+0.06)
Bioanalytical Systems to Release Third Quarter Fiscal 2015 Results on Thursday, August 13, 2015; Conference Call & Webcast Set For 11:00 a.m. EDT
BusinessWire - Mon Aug 10, 1:56PM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) announced today that it will report financial results for the third quarter of fiscal 2015 ended June 30, 2015, prior to the market opening on Thursday, August 13, 2015. A conference call has been scheduled at 11:00 a.m. Eastern Daylight Time (EDT) to discuss the results. To participate in the call, dial (866) 865-2633, using passcode 2120136.
BASI: 1.17 (+0.06)
BUYINS.NET: BASI SqueezeTrigger Price is $1.92. There is $75,840 That Short Sellers Still Need To Cover.
M2 - Mon Jul 20, 7:28AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Bioanalytical Systems Inc (NASDAQ:BASI) in real time and just received an alert that BASI is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 39500 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $1.92. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
BASI: 1.17 (+0.06)
BASi Announces Enhancements to the Company's Laboratory Information Management System (LIMS)
BusinessWire - Tue Jul 14, 2:59PM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) has entered into an agreement with PDS Life Sciences (PDS) to fully upgrade its laboratory information management system (LIMS) to Ascentos(TM). The new Ascentos software represents the next generation of preclinical research LIMS and is a fully integrated software solution that includes toxicology, clinical pathology, toxicokinetics and pathology modules that streamline data management and reporting.
BASI: 1.17 (+0.06)
